Verona Pharma Q4 2020 Earnings Report
Key Takeaways
Verona Pharma reported its financial results for the fourth quarter and full year ended December 31, 2020, along with a corporate update, highlighting positive Phase 2 results and ongoing Phase 3 program enrollment.
Positive Phase 2 results with pMDI ensifentrine in COPD were achieved.
Enrollment is ongoing in the ENHANCE Phase 3 program.
A debt finance facility of up to $30 million was secured, increasing financial flexibility.
A conference call was hosted to discuss the fourth quarter and full year 2020 financial results and corporate update.
Verona Pharma
Verona Pharma
Forward Guidance
Verona Pharma anticipates top-line data from the pilot COVID-19 study of ensifentrine in the second quarter of 2021 and expects to complete enrollment in the ENHANCE program in the second half of 2021. Top-line data from ENHANCE-2 is expected in the first half of 2022 and from ENHANCE-1 in the second half of 2022.